Table 3.
Some drugs that are affected by host pharmacogenetics and the resultant effect.
Antiretroviral drug | Enzyme involved | Effect |
---|---|---|
Efavirenz | CYP2B6 | Increase in efavirenz concentrations and increased risk of discontinuation [50–56] |
Nevirapine | CYP2B6 | Increase in nevirapine plasma concentrations and increase hypersensitivity adverse effect associated with nevirapine [57–60] |
Atazanavir | UGT1A1 | Hyperbilirubinemia (indirect plasma bilirubin increase) and jaundice [157–160] |
Tenofovir | ABCC2, ABCC4 | Renal function decline [161–163] |
Abacavir | HLA-B∗5701 | Hypersensitivity associated with abacavir [164–167] |